NCT04104607RecruitingPhase 1/2
First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration resistant prostate carcinoma
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Feb 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 21 Mar 2024
- Start date
- 15 Nov 2019
- Lead sponsor
- Universitaetsklinikum Tuebingen AöR
- Diseases
- Prostate cancer
- NCT number
- NCT04104607
- EU CT number
- 2024-512894-29-00
- EudraCT number
- 2019-000238-20
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 44
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR Coordinator of this site? Confirm its status | Berlin | Germany | Recruiting |
| Universitaetsklinikum Tuebingen AöR Coordinator of this site? Confirm its status | Tuebingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.